Abstract:Immunotherapy (IO), especially a subgroup called immune checkpoint inhibitors (ICIs) has revolutionized the treatment of a variety of cancers in past few years. ICIs include anti-PD-1 & anti-PD-L1 antibodies, as well as CTLA-4 inhibitors. Clinical trials showed that ~15% to 40% of cancer patients (sometime more) respond to ICIs (1,2). Time for response can be longer than those with traditional chemotherapy. Hence IOs may not be very appropriate for patients who require immediate cytoreduction for symptom relief or those near end-of-life. During initial phase of IO treatment, new lesions can occur as a result of inflammatory process, but they subsequent regress. This is called “pseudoprogression”. It occurs in ≤5% of cases (3). Some patients who do not meet the criteria of objective response on traditional RECIST criteria may achieve prolonged periods of stable disease that are clinically significant. This leads to the proposal of using iRECIST criteria in IO studies. On the other hand, ~10% (4) of patient may exhibit hyperprogression phenomenon (doubling of tumor growth rate within ≤12 wks after start of treatment). Some researchers suggested that hyperprogression might be more commonly seen in elderlies, and may be associated with certain gene mutations (2,4). If hyperprogression occurs, prognosis is usually poor. Switching to alternative systemic therapy or best supportive care may be considered if appropriate. Despite promising results published, most of the patients succumb after treatment. Only a minority of patient achieved durable response and have prolong survival. The majority of irAEs occur within first 4 months of ICI treatment, but irAEs can occur months after completion of IO (5). Some irAEs are devastating, long lasting and fatal. Severe flare up of psoriasis, pneumonitis, colitis, cardiac toxicities, neurological irAEs and graft rejection after transplant have been reported. In general, the overall toxicities leading to discontinuation treatment due to irAEs are higher with CTLA-4 inhibitors like ipilimumab than anti-PD1 therapy using nivolumab or pembrolizumab (6). Immune related colitis/gastrointestinal irAEs & hypophysitis may be more common in CTLA4 inhibitors. On the other hand, thyroid related irAEs, vitiligo, pneumonitis ± graft rejection may be more frequent in anti-PD1 therapy (2). The safety data for PD-L1 inhibitors are still maturing. Details of grading of various irAEs & their managements have been published (2,7) and will not be discussed in details here. Patients who develop grade 3–4 irAEs need prompt recognition, treatment and close monitoring of response to systemic steroid ± other immunomodulatory agent(s). Tailing down of steroid should be slow, at least over 4–6 wks to avoid recurrence of irAEs. At present, some clinical trials are exploring the role of combinations IOs with other IOs, novel agents, chemotherapy and radiotherapy. Higher treatment related toxicities are expected in combination treatments. Median progression-free survival (PFS) & median overall survival (OS) might be good enough outcome Editorial

Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors: A case series and systematic literature review

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease

Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Safety profiles in the use of immune checkpoint inhibitors by patients with cancer and pre-existing autoimmune diseases

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors: current status

Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events

Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

Immune Checkpoint Inhibitors Therapies in Patients with Cancer and Preexisting Autoimmune Diseases: A Meta-Analysis of Observational Studies.

Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events

Toxicity in the era of immune checkpoint inhibitor therapy

Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors

Immunotherapy for metastatic cancer patients: the current status, limitations, obstacles and future directions.